[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,997,418
  • Shares Outstanding, K 103,288
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -378 M
  • EBITDA $ -372 M
  • 60-Month Beta 2.22
  • Price/Sales 21.75
  • Price/Cash Flow N/A
  • Price/Book 2.85

Options Overview Details

View History
  • Implied Volatility 86.45% (+3.34%)
  • Historical Volatility 59.32%
  • IV Percentile 54%
  • IV Rank 42.85%
  • IV High 122.94% on 02/11/26
  • IV Low 59.10% on 04/13/26
  • Expected Move (DTE 16) 2.55 (9.00%)
  • Put/Call Vol Ratio 2.47
  • Today's Volume 222
  • Volume Avg (30-Day) 718
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 18,627
  • Open Int (30-Day) 18,491
  • Expected Range 25.77 to 30.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 5
  • High Estimate $-1.00
  • Low Estimate $-1.26
  • Prior Year $-1.10
  • Growth Rate Est. (year over year) -5.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.67 +15.20%
on 08/03/26
31.48 -9.72%
on 08/25/26
+2.90 (+11.36%)
since 07/31/26
3-Month
24.67 +15.20%
on 08/03/26
38.26 -25.72%
on 07/07/26
-0.54 (-1.86%)
since 06/02/26
52-Week
16.52 +72.03%
on 09/03/25
38.26 -25.72%
on 07/07/26
+12.11 (+74.25%)
since 09/02/25

Most Recent Stories

More News
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment...

BEAM : 28.67 (-1.21%)
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 28.67 (-1.21%)
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing...

BEAM : 28.67 (-1.21%)
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU  BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license...

BEAM : 28.67 (-1.21%)
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently...

BEAM : 28.67 (-1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 30.34
2nd Resistance Point 29.95
1st Resistance Point 29.49
Last Price 28.67
1st Support Level 28.63
2nd Support Level 28.23
3rd Support Level 27.77

See More

52-Week High 38.26
Fibonacci 61.8% 29.96
Last Price 28.67
Fibonacci 50% 27.39
Fibonacci 38.2% 24.82
52-Week Low 16.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.